{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:53Z","timestamp":1792985753883,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Trastuzumab deruxtecan (T-DXd) has been approved for the treatment of human epidermal growth factor receptor-2 (HER2)-positive gastric cancer and other indications in several countries and is considered moderately or highly emetogenic. The management of nausea and vomiting associated with T-DXd treatment has not been fully evaluated and the effectiveness of conventional prophylaxis remains unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This open-label, randomized, multicenter, phase 2 study aimed to investigate the optimal antiemetic therapy for Japanese patients with gastric cancer undergoing T-DXd treatment. Patients were randomized to a doublet regimen group (dexamethasone and palonosetron) or triplet regimen group (aprepitant, dexamethasone, and palonosetron) at a ratio of one to one, stratified by sex, gastrectomy status, and study institution. Both antiemetic treatments were administered from day 1 before T-DXd administration, and emetic events and nausea were observed for 21\u00a0days. The primary endpoint was the antiemetic complete response (CR) rate to assess control for emetic events based on voluntary patient-reported outcomes (PROs) during cycle 1 (1\u201321\u00a0days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 60 enrolled patients, 58 were eligible for inclusion in this analysis (29 patients in each regimen group). The overall CR rates for the doublet and triplet regimens were 41.4% (12\/29 patients) and 37.9% (11\/29 patients), respectively, and neither regimen met the pre-specified threshold (&gt;\u200918\/29 patients). The CR rate in the acute phase (0\u201324\u00a0h) was 86.2% (25\/29 patients) for both regimens, and the CR rates in the delayed phase (2\u201321\u00a0days) were 41.4% (12\/29 patients) and 37.9% (11\/29 patients) for the doublet and triplet regimens, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Given that the primary endpoint was not met, further research is needed to better characterize nausea and vomiting with T-DXd to tailor an anti-emetic regimen that suits the needs of the patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10147-025-02748-8","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:03:46Z","timestamp":1745823826000},"page":"1162-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-3800","authenticated-orcid":false,"given":"Toru","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michitaka","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenki","family":"Segami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"3","key":"2748_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2748_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ et al (2022) Gastric cancer, version 22022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(2):167\u2013192","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2748_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Van Cutsem E, Narita Y et al (2019) Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS. SSO and TOS Ann Oncol 30(1):19\u201333","journal-title":"SSO and TOS Ann Oncol"},{"issue":"3","key":"2748_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221","journal-title":"Lancet Oncol"},{"issue":"10294","key":"2748_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"issue":"2","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu MH, Kato K et al (2019) Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30(2):250\u2013258","journal-title":"Ann Oncol"},{"issue":"9742","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"1","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20(1):1\u201319","journal-title":"Gastric Cancer"},{"issue":"25","key":"2748_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419\u20132430","journal-title":"N Engl J Med"},{"issue":"4","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10120-021-01182-9","volume":"24","author":"G Roviello","year":"2021","unstructured":"Roviello G, Aprile G, D\u2019Angelo A et al (2021) Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? Gastric Cancer 24(4):765\u2013779","journal-title":"Gastric Cancer"},{"issue":"4","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","volume":"24","author":"K Shitara","year":"2021","unstructured":"Shitara K, Baba E, Fujitani K et al (2021) Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 24(4):780\u2013789","journal-title":"Gastric Cancer"},{"key":"2748_CR12","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology for Antiemesis, Version 1.2024-Dec 13, 2023"},{"key":"2748_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"key":"2748_CR14","unstructured":"Japan Society of Clinical Oncology (2015) The Japanese Guideline for the proper use of antiemetics"},{"issue":"25","key":"2748_CR15","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1002\/sim.5829","volume":"32","author":"W Hou","year":"2013","unstructured":"Hou W, Chang MN, Jung S et al (2013) Designs for randomized phase II clinical trials with two treatment arms. Statist Med 32(25):4367\u20134379","journal-title":"Statist Med"},{"issue":"11","key":"2748_CR16","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y et al (2017) Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 18(11):1512\u20131522","journal-title":"Lancet Oncol"},{"issue":"11","key":"2748_CR17","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/aje\/kwy158","volume":"187","author":"Y Hagiwara","year":"2018","unstructured":"Hagiwara Y, Fukuda M, Matsuyama Y (2018) The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol 187(11):2481\u20132490","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2748_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14740338.2017.1325868","volume":"16","author":"B Rapoport","year":"2017","unstructured":"Rapoport B, Smit T (2017) Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf 16(6):697\u2013710. https:\/\/doi.org\/10.1080\/14740338.2017.1325868. (PMID: 28460548)","journal-title":"Expert Opin Drug Saf"},{"key":"2748_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.001","author":"H Sakai","year":"2024","unstructured":"Sakai H, Tsurutani J, Ozaki Y et al (2024) A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001","journal-title":"Ann Oncol"},{"issue":"5","key":"2748_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-005-0788-5","volume":"13","author":"CT Liau","year":"2005","unstructured":"Liau CT, Chu NM, Liu HE et al (2005) Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians\u2019 and nurses\u2019 estimation vs patients\u2019 reported outcomes. Support Care Cancer 13(5):277\u2013286. https:\/\/doi.org\/10.1007\/s00520-005-0788-5","journal-title":"Support Care Cancer"},{"issue":"8","key":"2748_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","volume":"3","author":"E Basch","year":"2017","unstructured":"Basch E, Dueck AC, Rogak LJ et al (2017) Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials. JAMA Oncol 3(8):1043\u20131050","journal-title":"JAMA Oncol"},{"issue":"3","key":"2748_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10120-021-01164-x","volume":"24","author":"M Aoki","year":"2021","unstructured":"Aoki M, Iwasa S, Boku N (2021) Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 24(3):567\u2013576","journal-title":"Gastric Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02748-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T05:10:57Z","timestamp":1748495457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02748-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akitaka Makiyama has received honoraria from Eli Lilly Japan K.K, Bristol Myers Squibb K.K, Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Akira Ooki has received honoraria from Bristol Myers Squibb K.K, Ono Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Aya Katayama and Kazuhito Shiosakai are employees of Daiichi Sankyo Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study data and informed consent were obtained in accordance with the Declaration of Helsinki and were approved by the Ethics Review Board of each institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent or a substitute for it was obtained from all patients for inclusion in the present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}